

# Maximum Vasoactive Inotropic Score in the 48 Hours post-LVAD Implantation Predicts Early Severe Right Ventricular Failure

Salil Kumar, MD<sup>1</sup>, Syed Muhammad Ibrahim Rashid, MD<sup>1</sup>, Mohammad Hashim Mustehsan, MD<sup>1</sup>, Thiru Chinnadurai, MD<sup>1</sup>, Nitish Gupta, MD<sup>1</sup>, Omar Saeed, MD<sup>2</sup>, Snehal R. Patel, MD<sup>2</sup>, Sandhya Murthy, MD<sup>2</sup>, Jooyoung J. Shin, MD<sup>2</sup>, Stephen Forest, MD<sup>2</sup>, Sasha Vukelic, MD<sup>2</sup>, Daniel J. Goldstein, MD<sup>3</sup>, Ulrich P. Jorde, MD<sup>2</sup>, Daniel B. Sims, MD<sup>2</sup>

1. Houston Methodist DeBakey Heart & Vascular Center, Houston, TX  
2. Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.  
3. Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.  
4. Division of Anesthesia, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.  
5. Division of Cardiothoracic Surgery, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.

## BACKGROUND

- Right ventricular failure (RVF) remains a significant source of post-LVAD implantation morbidity and mortality.
- The vasoactive inotropic score (VIS) is an emerging novel way to estimate total inotropic and vasotropic support, and we believe the post-operative VIS score could correlate with severe RVF post-LVAD implantation.

## OBJECTIVE

- Determine if the post-operative VIS score correlates with severe early RVF.

## METHODS


- Single-center retrospective study of 240 patients over the age of 18 who received a continuous-flow durable LVAD between Jan 1, 2006 and Dec 31, 2017.
- VIS score was calculated as: dobutamine (mcg/kg/min) + 10 x milrinone (mcg/kg/min) + dopamine (mcg/kg/min) + 100 x epinephrine (mcg/kg/min) + 100 x norepinephrine (mcg/kg/min) + 10,000 x vasopressin (units/kg/min).
- VIS score at 6, 24, and 48 hours postoperatively were abstracted and then the maximum VIS score within 48 hours after implantation for each patient was used to stratify the cohort into quartiles.
- Severe RVF was defined as meeting criteria for clinical RVF and having inotropes > 14 days after implant, inotropes re-started after 14 days of implant, RVAD placement during implant admission, or death from RVF during implant admission.
- A univariate and multivariate logistic regression was performed to evaluate for predictors of severe early RVF.

## TABLE 1: PATIENT CHARACTERISTICS

|                               | All Patients<br>(n = 240) | VIS 0 -<br>10 (n =<br>72) | VIS 11 -<br>15 (n =<br>50) | VIS 16 -<br>22 (n =<br>61) | VIS 23 -<br>87 (n =<br>57) | P value |
|-------------------------------|---------------------------|---------------------------|----------------------------|----------------------------|----------------------------|---------|
| Mean VIS Score                | 18 ± 12                   | 7 ± 2                     | 13 ± 2                     | 19 ± 2                     | 33 ± 12                    |         |
| Age, year                     | 56 ± 13                   | 53 ± 13                   | 56 ± 14                    | 54 ± 12                    | 60 ± 11                    | 0.01    |
| BMI, m2/kg                    | 27 ± 7                    | 27 ± 8                    | 28 ± 6                     | 28 ± 7                     | 27 ± 7                     | 0.83    |
| Gender                        |                           |                           |                            |                            |                            | 0.12    |
| Female                        | 56 (23)                   | 23 (32)                   | 7 (14)                     | 12 (20)                    | 14 (25)                    |         |
| Male                          | 184 (77)                  | 49 (68)                   | 43 (86)                    | 49 (80)                    | 43 (75)                    |         |
| INTERMACS Level               |                           |                           |                            |                            |                            | 0.03    |
| 1                             | 33                        | 5                         | 12                         | 6                          | 10                         |         |
| 2                             | 48                        | 8                         | 11                         | 15                         | 14                         |         |
| 3                             | 139                       | 52                        | 21                         | 35                         | 31                         |         |
| 4                             | 19                        | 7                         | 5                          | 5                          | 2                          |         |
| LVAD Indication               |                           |                           |                            |                            |                            | 0.32    |
| Destination                   | 148 (62)                  | 41 (57)                   | 30 (60)                    | 35 (57)                    | 42 (74)                    |         |
| Bridge to transplant          | 58 (24)                   | 22 (31)                   | 12 (24)                    | 17 (28)                    | 7 (12)                     |         |
| Possible bridge to transplant | 34 (14)                   | 9 (12)                    | 8 (16)                     | 9 (15)                     | 8 (14)                     |         |
| Heart Failure Etiology        |                           |                           |                            |                            |                            | 0.42    |
| Nonischemic                   | 145 (60)                  | 48 (67)                   | 29 (58)                    | 38 (62)                    | 30 (53)                    |         |
| Ischemic                      | 95 (40)                   | 24 (33)                   | 21 (42)                    | 23 (38)                    | 27 (47)                    |         |
| LVAD Type                     |                           |                           |                            |                            |                            | 0.24    |
| HeartMate 2                   | 180 (75)                  | 50 (69)                   | 37 (74)                    | 45 (74)                    | 48 (84)                    |         |
| HeartMate 3                   | 26 (11)                   | 10 (14)                   | 8 (16)                     | 4 (7)                      | 4 (7)                      |         |
| HeartWare                     | 34 (14)                   | 12 (17)                   | 5 (10)                     | 12 (19)                    | 5 (9)                      |         |
| Total bilirubin, mg/dL        | 1.5 ± 1.1                 | 1.2 ± 0.8                 | 1.8 ± 1.3                  | 1.5 ± 1.2                  | 1.5 ± 1.2                  | 0.05    |
| Creatinine, mg/dL             | 1.5 ± 0.6                 | 1.4 ± 0.5                 | 1.5 ± 0.6                  | 1.6 ± 0.7                  | 1.6 ± 0.5                  | 0.11    |
| Pre-operative hemodynamics    |                           |                           |                            |                            |                            |         |
| Mean RA pressure (mmHg)       | 12 ± 7                    | 10 ± 7                    | 12 ± 7                     | 13 ± 7                     | 14 ± 7                     | 0.02    |
| Mean PA pressure (mmHg)       | 36 ± 10                   | 34 ± 11                   | 36 ± 7                     | 36 ± 11                    | 36 ± 10                    | 0.67    |
| PAPi                          | 3.8 ± 4.3                 | 4.3 ± 4.8                 | 3.7 ± 4.7                  | 3.4 ± 3.6                  | 3.6 ± 4.2                  | 0.72    |
| PCWP (mmHg)                   | 24 ± 9                    | 23 ± 10                   | 26 ± 8                     | 26 ± 10                    | 24 ± 8                     | 0.31    |
| Fick CI (L/min/m2)            | 2.0 ± 0.6                 | 2.0 ± 0.7                 | 2.0 ± 0.6                  | 2.1 ± 0.7                  | 2.1 ± 0.6                  | 0.76    |

## RESULTS

- The VIS quartiles groups were 0-10, 11-15, 16-22, and 23-87.
- Patients in quartile 4 were older, had a higher preoperative CVP and INTERMACS level (Table 1).
- In our univariate analysis, VIS quartile 4 was associated with severe RVF (OR 3.62, CI [1.37-9.56], p = 0.009).
- The multivariable model (which included age, INTERMACS level, total bilirubin over 2.5 mg/dL, RV dysfunction on echocardiogram, and gender) found that VIS quartile 4 independently correlated with severe RVF (OR 3.04, CI [1.5 - 8.83], p = 0.04).
- The ROC-curve for this model had an AUC of 0.68 (Figure 1).



## CONCLUSION

- Our results demonstrate that the highest VIS score within the first 48 hours after LVAD implantation correlates with severe RVF.
- This correlation could imply that higher vaso-inotropic support may be part of what precipitates severe RVF in these patients who have less RV reserve.
- Further work is needed to confirm this relationship.

- Drs. Jorde and Goldstein report serving as non-paid consultants for Abbott.
- Dr. Saeed is supported by the NIH/NHLBI (HL145140).